...
首页> 外文期刊>Proteomics >Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics
【24h】

Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics

机译:癌症临床生物标志物的发现与验证:结合代谢组织与蛋白质组学的评论

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Early detection and diagnosis of cancer can allow timely medical intervention, which greatly improves chances of survival and enhances quality of life. Biomarkers play an important role in assisting clinicians and health care providers in cancer diagnosis and treatment follow‐up. In spite of years of research and the discovery of thousands of candidate cancer biomarkers, only a few have transitioned to routine usage in the clinic. This review highlights advances in proteomics technologies that have enabled high rates of discovery of candidate cancer biomarkers and evaluates integration with other omics technologies to improve their progress through to validation and clinical translation. Furthermore, it gauges the role of metabolomics technology in cancer biomarker research and assesses it as a complementary tool in aiding cancer biomarker discovery and validation.
机译:摘要癌症的早期检测和诊断可以及时允许医疗干预,这大大提高了生存的机会,提高了生活质量。 生物标志物在协助临床医生和医疗保健提供者在癌症诊断和治疗随访中起着重要作用。 尽管有多年的研究和数千名候选癌症生物标志物的发现,但只有少数几乎没有过渡到诊所的常规用途。 该综述突出了蛋白质组学技术的进步,使候选癌症生物标志物的高速发现能够进行高速发现,并评估与其他OMICS技术的整合,以改善他们通过验证和临床翻译的进展。 此外,它衡量代谢组科技术在癌症生物标志物研究中的作用,并评估其作为辅助癌症生物标志物发现和验证的互补工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号